DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note published on Friday. The firm issued a hold rating on the stock.

A number of other research analysts have also commented on the stock. JMP Securities boosted their price target on shares of DBV Technologies from $4.00 to $5.00 and gave the company a market outperform rating in a research report on Wednesday, July 31st. HC Wainwright restated a buy rating and set a $5.00 target price on shares of DBV Technologies in a research report on Thursday.

DBV Technologies Stock Up 2.1 %

Shares of NASDAQ DBVT opened at $0.97 on Friday. The company has a market cap of $93.60 million, a P/E ratio of -1.15 and a beta of 0.68. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $3.70. The business has a 50-day simple moving average of $0.91 and a two-hundred day simple moving average of $1.31.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period in the previous year, the company posted ($0.26) earnings per share. Equities research analysts anticipate that DBV Technologies will post -1.22 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its position in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies accounts for approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.